LLY

1,075.18

+0.27%↑

JNJ

207.23

+0.6%↑

ABBV

227.72

+0.26%↑

UNH

325.11

-0.71%↓

AZN

91.53

+0.2%↑

LLY

1,075.18

+0.27%↑

JNJ

207.23

+0.6%↑

ABBV

227.72

+0.26%↑

UNH

325.11

-0.71%↓

AZN

91.53

+0.2%↑

LLY

1,075.18

+0.27%↑

JNJ

207.23

+0.6%↑

ABBV

227.72

+0.26%↑

UNH

325.11

-0.71%↓

AZN

91.53

+0.2%↑

LLY

1,075.18

+0.27%↑

JNJ

207.23

+0.6%↑

ABBV

227.72

+0.26%↑

UNH

325.11

-0.71%↓

AZN

91.53

+0.2%↑

LLY

1,075.18

+0.27%↑

JNJ

207.23

+0.6%↑

ABBV

227.72

+0.26%↑

UNH

325.11

-0.71%↓

AZN

91.53

+0.2%↑

Home・Akciju saraksts・Microbot Medical Inc

Microbot Medical Inc

Slēgts

2.18 4.81

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

2.18

Max

2.26

Galvenie mērījumi
By Trading Economics
Ienākumi	-77K -3.6M
Peļņas marža	-4,038.095
Darbinieki	20
EBITDA	-79K -3.6M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+299.54% upside

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	8.1M 148M
Iepriekšējā atvēršanas cena	-2.63
Iepriekšējā slēgšanas cena	2.18

Tehniskais rādītājs

By Trading Central

Pārliecība

Neutral Evidence

2.52 / 2.57 Atbalsts un pretestība

Microbot Medical Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 22. dec. 23:54 UTC

Galvenie tirgus virzītāji

Novo Nordisk ADRs Gain on FDA Approval of First GLP-1 in Pill Form

2025. g. 22. dec. 19:08 UTC

Iegādes, apvienošanās, pārņemšana

Correction to Alphabet to Buy Intersect Article

2025. g. 22. dec. 17:21 UTC

Iegādes, apvienošanās, pārņemšana

Alphabet to Buy Intersect for $4.75 Billion as AI-Investment Plans Grow -- Update

2025. g. 22. dec. 16:46 UTC

Iegādes, apvienošanās, pārņemšana

Alphabet to Buy Intersect for $4.75 Billion in Cash

2025. g. 22. dec. 23:50 UTC

Tirgus saruna

Nikkei May Decline as Yen Rebounds -- Market Talk

2025. g. 22. dec. 23:42 UTC

Tirgus saruna

Gold Hits Record High Amid Rising Geopolitical Risks -- Market Talk

2025. g. 22. dec. 22:31 UTC

Peļņas

Zhejiang Sanhua Intelligent Controls: Higher Demand for Air-Conditioning Components Supported Results >002050.SZ

2025. g. 22. dec. 22:31 UTC

Peļņas

Zhejiang Sanhua Intelligent Controls: Higher Demand for Refrigeration Supported Results >002050.SZ

2025. g. 22. dec. 22:30 UTC

Peļņas

Zhejiang Sanhua Intelligent Controls Sees 2025 Net CNY3.87B, Up 25% on Year >002050.SZ

2025. g. 22. dec. 21:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 22. dec. 21:50 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2025. g. 22. dec. 21:37 UTC

Iegādes, apvienošanās, pārņemšana

Capricorn: Project Is Contiguous to Capricorn's Golden Range, Fields Find Tenure

2025. g. 22. dec. 21:36 UTC

Iegādes, apvienošanās, pārņemšana

Capricorn to Pay A$500,000 Cash, A$4M in New Shares

2025. g. 22. dec. 21:35 UTC

Iegādes, apvienošanās, pārņemšana

Capricorn to Acquire Prospective Package From Tempest Minerals

2025. g. 22. dec. 21:35 UTC

Iegādes, apvienošanās, pārņemšana

Capricorn Metals to Buy Yalgoo Project Tenement Package for A$4.5M

2025. g. 22. dec. 20:54 UTC

Iegādes, apvienošanās, pārņemšana

Middle West Partners Buys Paul Stuart From Mitsui & Co.

2025. g. 22. dec. 20:52 UTC

Iegādes, apvienošanās, pārņemšana

HCL Technologies: HCLSoftware to Acquire Jaspersoft From Cloud Software Group >532281.BY

2025. g. 22. dec. 20:09 UTC

Tirgus saruna

U.S. Natural Gas Settles Lower in Choppy Trade -- Market Talk

2025. g. 22. dec. 19:56 UTC

Tirgus saruna

Crude Gains as U.S. Increases Actions Against Venezuela -- Market Talk

2025. g. 22. dec. 19:49 UTC

Iegādes, apvienošanās, pārņemšana

A Topsy-Turvy Year for Oracle and the Ellisons Will Bleed into 2026 -- Barrons.com

2025. g. 22. dec. 19:23 UTC

Tirgus saruna

Mexico's Inflation Seen Easing in Early December -- Market Talk

2025. g. 22. dec. 19:23 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 22. dec. 19:02 UTC

Tirgus saruna

Global Energy Roundup: Market Talk

2025. g. 22. dec. 19:02 UTC

Tirgus saruna

Precious Metals Climb to New Heights -- Market Talk

2025. g. 22. dec. 18:45 UTC

Tirgus saruna

Canadian Trade-Exposed Industries At Forefront of Job Weakness -- Market Talk

2025. g. 22. dec. 18:30 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Intersect Selling Portion of Assets as Part of Alphabet Deal -- Market Talk

2025. g. 22. dec. 18:23 UTC

Iegādes, apvienošanās, pārņemšana

What Yogi Berra Would Say About the Talks to Take Over Warner Bros. Discovery -- Barrons.com

2025. g. 22. dec. 17:20 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2025. g. 22. dec. 17:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2025. g. 22. dec. 17:06 UTC

Iegādes, apvienošanās, pārņemšana

Alphabet to Buy Intersect for $4.75B as AI-Investment Plans Grow -- Update

Salīdzinājums

Cenas izmaiņa

Microbot Medical Inc Prognoze

Cenas mērķis

By TipRanks

299.54% augšup

Prognoze 12 mēnešiem

Vidējais 8.75 USD 299.54%

Augstākais 12 USD

Zemākais 5.5 USD

Pamatojoties uz 2 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Microbot Medical Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

2 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 2 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Microbot Medical Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

2.52 / 2.57Atbalsts un pretestība

The bullish and bearish events are balanced.

Recent bullish events outweigh bearish events.

All events are bullish.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Microbot Medical Inc

Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces. It also provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter. The company has a strategic collaboration agreement with Stryker Corporation for technology co-development; and Phase 2 collaboration agreement with Corewell Health for the development of LIBERTY endovascular robotic system. Microbot Medical Inc. was founded in 2010 and is based in Braintree, Massachusetts.